The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles.
anti-PD1 antibody
extracellular vesicles
hyperprogressive disease
immune checkpoint inhibitors
macrophages
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 Dec 2022
13 Dec 2022
Historique:
received:
07
09
2022
revised:
03
12
2022
accepted:
09
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
Hyperprogressive disease (HPD), an aggressive acceleration of tumor growth, was observed in a group of cancer patients treated with anti-PD1/PDL1 antibodies. The presence of a peculiar macrophage subset in the tumor microenvironment is reported to be a sort of "immunological prerequisite" for HPD development. These macrophages possess a unique phenotype that it is not clear how they acquire. We hypothesized that certain malignant cells may promote the induction of an "HPD-related" phenotype in macrophages. Bone-marrow-derived macrophages were exposed to the conditioned medium of five non-small cell lung cancer cell lines. Macrophage phenotype was analyzed by microarray gene expression profile and real-time PCR. We found that human NSCLC cell lines, reported as undergoing HPD-like tumor growth in immunodeficient mice, polarized macrophages towards a peculiar pro-inflammatory phenotype sharing both M1 and M2 features. Lipid-based factors contained in cancer cell-conditioned medium induced the over-expression of several pro-inflammatory cytokines and the activation of innate immune receptor signaling pathways. We also determined that tumor-derived Extracellular Vesicles represent the main components involved in the observed macrophage re-education program. The present study might represent the starting point for the future development of diagnostic tools to identify potential hyperprogressors.
Identifiants
pubmed: 36555441
pii: ijms232415802
doi: 10.3390/ijms232415802
pmc: PMC9779478
pii:
doi:
Substances chimiques
Culture Media, Conditioned
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Association for Cancer Research
ID : 20554
Références
MAbs. 2021 Jan-Dec;13(1):1954136
pubmed: 34313545
JTO Clin Res Rep. 2020 Feb 11;1(1):100001
pubmed: 34589908
Science. 2017 May 5;356(6337):513-519
pubmed: 28473584
Eur J Pharm Biopharm. 2020 Jan;146:55-63
pubmed: 31805356
Cancers (Basel). 2021 Sep 20;13(18):
pubmed: 34572931
Int J Mol Sci. 2021 Jun 18;22(12):
pubmed: 34207286
J Immunol Methods. 2020 Mar;478:112721
pubmed: 32033786
J Immunol Res. 2019 Nov 4;2019:1919082
pubmed: 31781673
PLoS One. 2016 Dec 29;11(12):e0168793
pubmed: 28033353
Cancer Immunol Res. 2021 Mar;9(3):309-323
pubmed: 33361087
Oncoimmunology. 2021 Feb 22;10(1):1887552
pubmed: 33680573
Shock. 2016 Aug;46(2):122-31
pubmed: 26954942
Int J Oncol. 2021 May;58(5):
pubmed: 33760183
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Mol Med. 2021 Sep 28;27(1):121
pubmed: 34583655
Biomark Res. 2022 Jan 27;10(1):5
pubmed: 35086565
Clin Cancer Res. 2019 Feb 1;25(3):989-999
pubmed: 30206165
Front Cell Dev Biol. 2021 Oct 08;9:746432
pubmed: 34692700
Sci Rep. 2014 Jul 18;4:5750
pubmed: 25034888
Immunopharmacol Immunotoxicol. 1999 Aug;21(3):565-82
pubmed: 10466080
Cancer Res. 2016 Jun 1;76(11):3189-99
pubmed: 27197187
Hepatology. 2019 Jul;70(1):198-214
pubmed: 30810243
PLoS One. 2020 Jul 13;15(7):e0236038
pubmed: 32658933
J Mol Endocrinol. 2022 May 23;69(2):315-327
pubmed: 35604113
Biochim Biophys Acta. 2015 Jul;1852(7):1540-9
pubmed: 25912735
Sci Transl Med. 2022 Nov 23;14(672):eabq7019
pubmed: 36417489
Front Oncol. 2022 Feb 10;11:662723
pubmed: 35223446
J Exp Clin Cancer Res. 2020 Nov 9;39(1):236
pubmed: 33168050
Nat Genet. 2006 May;38(5):500-1
pubmed: 16642009
Front Immunol. 2020 Dec 03;11:583084
pubmed: 33365025
Pharmacol Ther. 2017 Sep;177:81-95
pubmed: 28245991
Front Immunol. 2022 Jan 28;13:807050
pubmed: 35154124
J Thorac Oncol. 2020 Mar;15(3):360-370
pubmed: 31634668
Mol Ther. 2013 Feb;21(2):409-22
pubmed: 22929659
PLoS One. 2017 Jul 17;12(7):e0181125
pubmed: 28715437
Exp Hematol. 1999 Feb;27(2):337-44
pubmed: 10029173
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
J Clin Invest. 2015 Nov 2;125(11):4149-59
pubmed: 26436647
Cancers (Basel). 2020 May 23;12(5):
pubmed: 32456204
Cancers (Basel). 2019 Aug 27;11(9):
pubmed: 31461915
Nat Commun. 2021 Jan 28;12(1):647
pubmed: 33510144
J Thorac Oncol. 2022 Oct;17(10):1178-1191
pubmed: 35798240
Front Immunol. 2020 Apr 15;11:625
pubmed: 32351507
Int Immunol. 2021 Mar 1;33(3):127-148
pubmed: 33337480
J Leukoc Biol. 2019 Aug;106(2):345-358
pubmed: 30576000
Cell Biosci. 2019 Jul 03;9:55
pubmed: 31304005
Front Immunol. 2018 Mar 12;9:444
pubmed: 29593717
Br J Cancer. 2010 May 25;102(11):1555-77
pubmed: 20502460
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
Front Oncol. 2020 Feb 25;10:188
pubmed: 32161718
Oncol Ther. 2018 Dec;6(2):109-127
pubmed: 32700032
Int J Cancer. 2018 Oct 1;143(7):1741-1752
pubmed: 29667169
Cancers (Basel). 2021 Jul 22;13(15):
pubmed: 34359572
Front Immunol. 2019 Jul 31;10:1818
pubmed: 31417576
J Clin Invest. 2013 Aug;123(8):3363-72
pubmed: 23863624
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Front Cell Dev Biol. 2021 Sep 17;9:732192
pubmed: 34604233
J Clin Invest. 2005 Aug;115(8):2223-33
pubmed: 16025156
Br J Cancer. 2008 Jul 22;99(2):245-52
pubmed: 18594528
Cell Death Dis. 2022 Apr 20;13(4):382
pubmed: 35443741
Clin Cancer Res. 2016 Jan 15;22(2):436-47
pubmed: 26324743
Bioinformatics. 2007 Dec 1;23(23):3251-3
pubmed: 17644558
BMC Med. 2022 May 13;20(1):187
pubmed: 35550592
Sci Signal. 2016 Jun 28;9(434):ra64
pubmed: 27353364
Int J Mol Sci. 2019 Jul 06;20(13):
pubmed: 31284572
Cancers (Basel). 2021 Aug 13;13(16):
pubmed: 34439233